ABstrAct: Partial neutralization of bone morphogenetic protein 15 (BMP15) bioactivity by immunization is known to increase ovulation rate in sheep. However, it remains uncertain whether BMP15 vaccination would be a suitable procedure for increasing lambing rate. The aim of this study was to compare the efficacy of a BMP15 vaccination treatment on lamb production to that of commercially-available androstenedione-based vaccines that are used for this purpose. Ewes were immunized for 3 yr against androstenedione, BMP15, or no antigen (control). Vaccination with androstenedione or BMP15 altered (P < 0.05) ovulation rate as well as litter size at midpregnancy, birth, and weaning compared with controls. No differences were detected in the proportions of ewes conceiving in the first cycle or partial failure of multiple ovulations. Both gender and litter size affected birth weight of the lamb (P < 0.05), but no effect of treatment was found. Growth rate was significantly affected (P < 0.05) by gender, birth weight, and the number of lambs raised, but not treatment. In conclusion, immunization against either androstenedione or BMP15 increased ovulation rate. Androstenedione vaccination also increased the number of lambs weaned (P < 0.05). Bone morphogenetic protein 15 vaccination altered the pattern of the number of lambs weaned, but no increase in lamb production was observed as more ewes produced zero or three lambs. Overall, androstenedione or BMP15 vaccination did not significantly affect embryo or fetal survival or lamb performance independently of the effects of these treatments on ovulation rate.
INtrODuctION
Increasing ovulation rate in ewes to enhance the number of lambs weaned per ewe mated is a key driver of profitability (Amer, 2000; Borg et al., 2007) . A number of validated procedures to increase ovulation rate are available for practical application by farmers. For instance, provision of additional nutrition to the ewe in the weeks leading up to breeding increases ovulation rate (reviewed by Scaramuzzi et al., 2006) . Likewise, immunization against androstenedione is used widely in New Zealand to increase ovulation rate (Scaramuzzi et al., 1977) . Moreover, in recent years, several sheep lines have been identified with genetic mutations that increase ovulation rate and thus litter size (McNatty et al., 2005; Scaramuzzi et al., 2011) .
Currently, the mutations linked to increased ovulation rate are part of the transforming growth factor β superfamily pathway. Two of these are the oocyte-derived growth factors, bone morphogenetic protein 15 (BMP15) and growth differentiation factor 9 (GDF9; . Based on the known increase of fecundity in ewes heterozygous for inactivating mutations in the BMP15 gene (Galloway et al., 2000) ; it is hypothesized that immunization against BMP15 would increase lambing rate. We have previously shown that immunization against BMP15 or GDF9 increases ovulation rate in sheep , and thus these reagents may be beneficial for increasing litter size. However, the effects of immunizing against BMP15 on variables such as embryo, fetal, and lamb survival, as well as lamb growth rate to weaning, are unknown as are the effects of immunization over successive years. The objectives of the studies reported herein were to determine the effects of immunization against BMP15 on ovulation rate, embryo and fetal and lamb survival, and lamb growth. The response to BMP15 immunization was compared to that in ewes that were not immunized or were immunized with androstenedione-based vaccines.
MAtErIALs AND MEtHODs
The experiment was approved by an AgResearch Animal Ethics Committee and conforms to the 1999 Animal Protection (Codes of Ethical Conduct) Regulations of New Zealand.
Experimental Design
In this experiment, the efficacies of three twinning methodologies were tested in Romney ewes on the AgResearch Invermay research farm in the South Island of New Zealand. All ewes (n = 408) were approximately 1.5 yr of age at the initiation of the experiment, and the average weight of ewes in each group ranged between 56 and 57 kg. All animals had access to water and pasture ad libitum and had been immunized against Toxoplasma gondii and Campylobacter fetus fetus/Campylobacter jejuni (Toxovax and CampyVax4, MSD Animal Health; Upper Hutt, New Zealand) as part of normal animal practice in New Zealand. The ewes were assigned randomly to one of four treatment groups (n = 100 to 104 per group): Group 1 (Control) did not receive any immunization treatment to influence ovulation rate; Group 2 (Androvax) was immunized with Androvax/Androvaxplus (MSD Animal Health; androstenedione-based vaccine) according to manufacturer's instructions; Group 3 was immunized with Ovastim (Virbac Animal Health, Milperra, NSW, Australia; androstenedione-based vaccine) according to manufacturer's instructions; and Group 4 was immunized with the BMP15 peptide (SEVPGPSREHDGPESC) conjugated to BSA . Once assigned to a specific treatment, each ewe remained in that treatment group for the duration of the trial.
All the aforementioned vaccines included a 5% DE-AE-Dextran-based adjuvant and consisted of two injections in yr 1 (a sensitizer and booster injection 4 wk apart) and a single booster injection in yr 2 and 3 of the trial. Blood samples (10-mL Vacutainer tubes; CDC Southern, Dunedin, New Zealand) were collected from ewes at the time of immunization and 2 wk after the booster immunization in yr 1, and again at time of booster immunization and 2 wk after the booster in yr 2 and 3. Blood was placed in the refrigerator overnight and sera collected after centrifugation at approximately 1800 g for 20 min at 4°C. Sera were stored at -20°C until assayed. The average weight of the ewes in each treatment group in the second and third year of the experiment ranged between 57 and 58 kg and 61 to 64 kg, respectively. The introduction of rams after the booster immunizations were as recommended by the manufacturers or as determined in preliminary studies for BMP15 (range 2 to 4 wk). However, the vaccinations dates were varied between treatments to allow the rams to be introduced to the ewes on the same day. The immunization details for the BMP15 peptide vaccine were as follows: each immunization consisted of 0.2 mg of BMP15-BSA peptide conjugate given in 1 mL of 5% DEAE-Dextran. Rams were introduced 2 wk after the booster immunization. Ewes were mated in single-sire mating groups with ewes from each group being evenly split across different mating sires.
In the first year of the trial, rams were 8 to 9 mo of age, whereas mature rams (1.5 yr of age or greater) were used in the second and third years of the trial.
On d 17 to 21 after ram introduction, ovulation rate was determined by laparoscopic observation of the ovaries and counting the number of corpora lutea. The numbers of fetuses present at midpregnancy were identified by ultrasound scanning of the ewes 77 to 88 d after ram introduction using a commercial operator unaware of the treatments. The number of lambs was determined from twice daily checks of all ewes to assign individual lambs born dead or alive to specific ewes as well as to record the birth weight and gender of each lamb. At approximately 4 wk of age (at the time of tail docking), the lambs were vaccinated against Scabby Mouth using Scabigard (Pfizer Animal Health; Auckland, New Zealand) and given a vitamin B12 supplement (B12 2000, Novartis New Zealand Ltd) according to manufacturers' instructions. Male lambs were also castrated using a rubber ring at this time. All lambs were weaned on the same day each year and average daily gain was calculated by subtracting weight at birth from weight at weaning and dividing by the age of the lamb.
Detection of Antibody Response to BMP15 Vaccination
To confirm that the noncommercial BMP15 vaccination regimen was effective in generating antibodies against BMP15, an ELISA-based assay was used to detect antibody titers in ≥45 animals selected randomly for each year of the experiment. The detection of antibodies against BMP15 was as previously described (Juengel et al., 2002 using 0.5 μg/well of E. coli-produced ovine BMP15 (mature region) as the coating antigen, a 1:10,000 dilution of the sheep serum samples, and a 1:5000 dilution of anti-sheep IgG-horseradish peroxidize second antibody (Sigma, Auckland, New Zealand). In each assay, quality control samples were also included in each plate to allow the determination of inter-and intraassay coefficients of variations. The average inter-and intraassay coefficients of variation for all assays were <15%.
Statistical Analyses
Average optical density readings obtained from assays for determining immune response in samples collected pre-and postimmunization were compared for the BMP15 immunization for each year using a paired t test. The effects of treatments on ovulation rate, conception rate from the measured ovulation rate, embryo and fetus survival, and number of lambs weaned were determined. The proportion of male and female lambs, lamb birth weights, and lamb growth rates were also examined. Average ovulation rate was examined using REML. Analyses were undertaken for each year separately for ovulation rate as a significant year by treatment interaction was noted (P < 0.001). Body weight during the premating interval was also found to be a significant factor (P < 0.001) and was retained in the model. Differences in the distribution of ovulation rate classes among treatments were examined using generalized linear interactive modeling (GLIM) with binomial distribution and a logit link. Average litter size at midpregnancy, birth, and weaning was examined using REML including treatment, year, treatment by year interactions, and weight premating as fixed variables and mate-sire and ewe as random factors. While year was a significant factor (P < 0.001) for all three measurements, no significant interactions were observed between year and treatment and therefore, data for the 3 yr were combined for the final analyses. Differences in the distribution of litter size classes at scanning, birth, and weaning among treatments were examined using GLIM with binomial distribution and a logit link including year in the model. Ewes that lambed within 148 d of the day that ovulation rate was measured were considered to have conceived in the first breeding cycle whereas those that lambed after 148 d were considered not to have conceived in the first breeding cycle. Differences among treatment groups were compared using GLIM with binomial distribution and a logit link including year in the model. For evaluation of partial failure of multiple ovulations, only ewes that had lambed within the 148 d from the measured ovulation rate were examined to exclude ewes that may not have been bred. As embryo and fetal survival for an individual ovum is affected by ovulation rate, analysis was restricted to those ewes ovulating two ova as this was the most common observation when considering all treatments. The distribution of numbers of lambs born to these ewes was compared using GLIM with binomial distribution and a logit link including year in the model.
The proportion of male and female lambs born to ewes from each treatment group was compared with GLIM with binomial distribution and a logit link including year in the model. The effects of treatment on birth weight of lambs was parsimoniously modeled with the factors, year, gender of lamb, size of litter (including both live and dead littermates), sire, and size of litter by year interactions accounted for in the model as these all had significant effects on birth weight. Average daily gain of the lambs was parsimoniously modeled with the factors of gender of the lamb, birth weight of the lamb, number of lambs reared by dam, sire, and birth weight by year, and birth weight by number of lambs reared by dam interactions, as all had a significant effect. No other interactions between three or two factors were observed. Differences in lamb survival to weaning among treatments was examined using GLIM with binomial distribution and a logit link including year and birth weight classification (grouped as ≥3.0 kg, >3.0 to 3.5 kg, >3.5 to 4.0 kg, >4.0 to 4.5 kg, >4.5 to 5.0 kg, >5.0 to 5.5 kg, >5.5 to 6.0 kg, >6 kg) in the model.
rEsuLts

Ovulation Rate and Litter Size at Mid-Pregnancy, Birth, and Weaning
The BMP15 vaccination treatment induced the expected immune response as determined by detection of antibodies in sera (Table 1) . Anovulation was relatively rare in the treatment groups, with <0.5% of ewes failing to ovulate in the control and androstenedione treated ewes, and <2% of ewes immunized against BMP15 failing to ovulate. While the effects of the different vaccination treatments on ovulation rate varied from year to year, those against androstenedione increased ovulation rate with no observable difference between the two commercial products (Table 2) . Immunization against BMP15 also affected ovulation rate in yr 2 and 3, with an increased number of ewes with very high ovulation rates (≥4). The androstenedione immunizations increased litter size at midpregnancy (Table 3) , birth (Table 4) , and weaning (Table 5 ). This was due to a decrease in the number of ewes with single lambs and an increase in the number carrying twin and triplet (or quadruplet) lambs at midpregnancy and birth, although ewes weaned at most three lambs. Immunization against BMP15 also increased litter size at midpregnancy and birth, but there was no increase in litter size observed at weaning. A decrease in the numbers of ewes with single and twin lambs was noted with increased numbers of ewes with triplet (or quadruplet/ quintuplet) lambs noted at midpregnancy and at birth.
Conception Rate and Partial Loss of Multiple Ovulation
The average conception rate during the first breeding cycle was not affected by any of the vaccines (Table 6 ). In addition, the failure of multiple ovulations to yield an equivalent number of lambs at midpregnancy or birth (partial loss of multiple ovulation) did not differ between the treatment groups (Table 6 ) when examined in twin ovulating ewes. The majority of losses were observed before ultrasound scanning at midpregnancy, with losses between midpregnancy and birth <5% in each treatment (Tables 3 and 4) .
Lamb Performance
Lamb birth weight and lamb growth rate were not affected by treatment (Table 7) . The vaccines did not alter the proportion of female lambs compared to controls (Table 7) . However, a lower proportion of female lambs were noted in the ewes treated with the Ovastim vaccine when compared to the ewes treated with the Androvax or BMP15 vaccines. No effects of treatments were observed on lamb survival (Table 7) .
DIscussION
While immunization against BMP15 clearly increased ovulation rate, the number of lambs weaned was not found to have increased. This was likely to be related to an increased number of animals that ovulated a high number of ova thereby leading to an increased number of ewes that failed to maintain a pregnancy or who failed to wean any lambs due to the increased risks associated with litters of three or more lambs.
This variability in response among ewes immunized against BMP15 most likely reflects the amount of freely a,b Within each year, the means and proportional responses to each treatment not sharing a common alphabetical superscript are different from one another (P < 0.05). Note, differences in distributions of ewes ovulating 0 to 1, 2, 3 or ≥4 among treatments are indicated with differing superscripts on the 0 to 1 category.
1 Note, rounding of percentages accounts for some treatments not equaling 100%.
2 For yr 1, ewes with ovulation rates of 3 or greater were combined for statistical analysis. The means and proportional responses to each treatment not sharing a common alphabetical superscript are different from one another (P < 0.05). Note, differences in distributions of ewes with litter size of 0, 1, 2 or ≥3 among treatments are indicated with differing superscripts on the 0 category.
1 Note, rounding of percentages accounts for some treatments not equaling 100%. The means and proportional responses to each treatment not sharing a common alphabetical superscript are different from one another (P < 0.05). Note, differences in distributions of ewes with litter size of 0, 1, 2 or ≥3 among treatments are indicated with differing superscripts on the 0 category.
available bioactive BMP15 and interactive effects of BMP15 with the nutritional status of the ewes. Previous studies have shown that the heterozygous BMP15 mutant Inverdale ewes, which are likely to have lower bioactive levels of BMP15, are more sensitive to nutritionally-driven increases in ovulation rate (Demmers et al., 2011) .
Bone morphogenetic protein 15 is known to be essential for normal ovarian follicular development as sheep homozygous for inactivating mutations in BMP15 are sterile with primary ovarian failure (Galloway et al., 2000) . Furthermore, previous studies have shown that immunization using an oil-based adjuvant to elicit a strong immune response leads to an inhibition of ovarian follicular growth and anovulation that can last a significant length of time (months; Juengel et al., 2002; Juengel et al., 2011) . Thus, the failure of some BMP15 vaccinated animals to ovulate was most likely the result of induced anovulation as a result of normal ovarian follicular development being compromised.
Extremely high ovulation rates have also been linked to limiting the amount of bioactive BMP15. Ovulation rates of up to 10 have been observed in previous immunization trials using oil-based adjuvants (Juengel et al., 2002) . Furthermore, animals with mutations in multiple genes acting through the TGFB pathway also have high ovulation rates. For example, sheep that are heterozygous for mutations in the Inverdale gene (BMP15), as well as the Booroola and Woodlands mutations, both of which have been shown to suppress BMP15 mRNA expression (Feary et al., 2007; Crawford et al., 2011) , have high ovulation rates .
An important finding of this study was that immunization against BMP15, an oocyte-produced protein, did not directly affect survival of the embryo and fetus or lamb performance to weaning, as no differences were observed in lamb performance when litter size was accounted for in the model. Lowering of BMP15 concentrations in vivo, such as occurs in ewes heterozygous for inactivating mutations in BMP15, does not reduce embryo or fetus survival or lamb performance (Davis et al., 1993; Demmers et al., 2011) . However, addition of BMP15 and GDF9 to media during IVM procedures has improved blastocyst rate suggesting that these oocyte-produced factors might be important for oocyte maturation (Hussein et al., 2006) . This might be a consequence of removing a cumulus-oocyte complex from a growth factor-enriched environment when transferring the complex into culture media. Hitherto, it was not clear whether active immunization against an oocyte-produced protein would negatively influence oocyte function through an increased interaction with the immune system. A previous study did not show any obvious effects of BMP15 immunization on embryo or fetal survival , but the number of animals studied may have been insufficient to observe any subtle effects. Nonspecific damage of the oocyte through immune recognition does not appear to be a major factor to be overcome when developing fecundity-based vaccines against oocyte secreted proteins.
The effects of the androstenedione vaccines were as expected and served as a positive control in which to compare the effects of the BMP15 vaccine. Overall, the two different androstenedione vaccines had similar responses; although for both vaccines, the effects varied across the years. This variability of response highlights one of the limitations of the vaccines (Stubbings and Maund, 1988) . The means and proportional responses to each treatment not sharing a common alphabetical superscript are different from one another (P < 0.05). Note, differences in distributions of ewes with litter size of 0, 1, 2 or ≥ 3 among treatments are indicated with differing superscripts on the 0 category.
The cause of this variability is currently not fully understood but could include differing response of animals in different nutritional states (Stubbings and Maund, 1988) or interactions between the vaccine and compounds capable of binding to the estrogen receptor (i.e., zearalenone or phytoestrogens from clover; Smith and Morris, 2006) .
Previous studies examining the effects of immunization against androstenedione on conception rate, embryo survival, and lamb performance have been inconsistent but highlight the potential for negative effects of the vaccines on these traits (Boland et al., 1986; Cameron et al., 1988; Croker et al., 1988; Scaramuzzi et al., 1993) . Expression of the androgen receptor is widespread in the sheep ovary, but it is unclear if androgens may have a direct effect on the oocyte, as receptors have been noted in oocytes using immunohistochemistry, but no mRNA for androgen receptor could be detected with in situ hybridization (Juengel et al., 2006) . In addition, altering androgen production has previously been linked to a reduced number of normal oocytes (Moor et al., 1980; Osborn et al., 1986) . Androgen receptors have also been detected in the oviduct and uterus (Wilson and McPhaul, 1996; Okada et al., 2003; Hayashi et al., 2008) . Furthermore, treatment of ewes with exogenous androgens between d 30 to 90 of pregnancy is known to have effects on multiple systems in the ewe including lowering the birth weight of the lamb (Padmanabhan et al., 2010) . Thus a reduced amount of bioavailable androgens could potentially create problems by influencing oviduct, uterine, or placental function.
However, similar to what was seen with the BMP15 vaccine, the effects of immunization against androstenedione appear primarily limited to alterations in ovulation rate as no differences were observed in conception rate or partial failure of multiple ovulations. Previous studies have shown detrimental effects of immunization against androstenedione on conception rate and early development of the embryo (Boland et al., 1986; Cameron et al., 1988; Scaramuzzi et al., 1993) . However, controlling the timing of mating after the booster immunization appears to be a key element in minimizing these detrimental effects as ewes mating 14 d after the booster immunization were more severely affected than those mated 25 d (Boland et al., 1986) . In the present study, ewes were not exposed to rams until 4 wk after the booster immunization with the androstenedione-based vaccines as recommended by the manufacturers and thus this potentially detrimental effect on conception rate and partial failure of multiple ovulations was minimized.
One unexpected finding was the small effect of immunization with Ovastim on the gender ratio of the lambs, with more male lambs being born compared to that for BMP15 or Androvax, but not control immunized ewes. Previous studies have shown a potential effect of follicular fluid testosterone concentrations on gender ratio of bovine embryos produced in vitro (Grant et al., 2008) but other studies have failed to find such an effect (Garcia-Herreros et al., 2010) . More studies are needed to determine if this effect of Ovastim vaccine is a consistent phenomenon and, if so, what the potential mechanisms of action might be given that another commercial vaccine against androstenedione, Androvax, did not appear to have any such bias.
Once litter size was accounted for, no differences were observed in birth weight or performance of the lambs. While multiple studies have observed that the increase in ovulation rate observed with immunization against androstenedione is not always associated with an increase in the number of lambs weaned, and in fact may be associated with numerically fewer lambs weaned (Alifakiotis, 1986; Croker et al., 1988) , the effects of increased litter size on lamb birth weight, survival, and growth were not examined in the analysis. All of these parameters are known to be affected by litter size (Morris et al., 2003; Kerslake et al., 2005; Peterson et al., 2006) and modeling of the data indicated that when changes in litter size are accounted for, no effects were observed in lamb performance.
Collectively, as was observed for the BMP15 vaccine, the effects of immunization against androstenedione to increase lambing seems to be through alteration of the mechanisms controlling the number of follicles developed for ovulation, with little or no evidence for an effect on downstream traits such as conception rate, partial failure of multiple ovulations, or lamb performance that was independent of a change in ovulation rate and thus litter size.
The vaccine against BMP15 significantly influenced ovulation rate and consequently lambing. However, for lamb production, this was not an improvement on currently available methods as increased numbers of nonpregnant ewes and ewes with three or more lambs were often observed. The androstenedione-based vaccines on average increased the number of lambs born per 100 ewes to 120 ± 5% (range 110 to 135% over the 3 yr) and the number of lambs weaned per 100 ewes to 115 ± 4% (range 106 to 140% over the same period) compared to the control ewes and this average increase is of economic significance for farmers (Amer, 2000; Borg et al., 2007) . However, the variability of the response to the vaccines from year to year underscores the need for continued improvement of technologies to improve lambing rate to achieve more consistent and predictable increases in lamb production if the full benefits are to be achieved.
While the current vaccine protocol tested for altering BMP15 bioavailability proved unsuitable for increasing lambing rate, it is possible that alternative procedures to regulate BMP15 in a more consistent manner may be worthwhile given that immunoneutralization of BMP15
